{"id":"https://openalex.org/W4282978207","doi":"https://doi.org/10.1158/1538-7445.am2022-lb004","title":"Abstract LB004: Upregulation of STAT3 signaling in tumor cells fosters a TME-dependent secondary resistance of BRCA1-deficient HGSOC to PARP inhibition","display_name":"Abstract LB004: Upregulation of STAT3 signaling in tumor cells fosters a TME-dependent secondary resistance of BRCA1-deficient HGSOC to PARP inhibition","publication_year":2022,"publication_date":"2022-06-15","ids":{"openalex":"https://openalex.org/W4282978207","doi":"https://doi.org/10.1158/1538-7445.am2022-lb004"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2022-lb004","doi":"https://doi.org/10.1158/1538-7445.am2022-lb004","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2022-lb004","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5050953889","display_name":"Liya Ding","orcid":"https://orcid.org/0009-0007-9327-2716","observed_orcids":["https://orcid.org/0009-0007-9327-2716"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Liya Ding","raw_affiliation_strings":["1Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100617678","display_name":"Qiwei Wang","orcid":"https://orcid.org/0000-0003-3897-2529","observed_orcids":["https://orcid.org/0000-0003-3897-2529"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Qiwei Wang","raw_affiliation_strings":["1Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110587291","display_name":"Michael Kearns","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael Kearns","raw_affiliation_strings":["1Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073511696","display_name":"Tao Jiang","orcid":"https://orcid.org/0000-0002-6008-9049","observed_orcids":["https://orcid.org/0000-0002-6008-9049"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Tao Jiang","raw_affiliation_strings":["1Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002633543","display_name":"Xin Cheng","orcid":"https://orcid.org/0000-0001-7816-0547","observed_orcids":["https://orcid.org/0000-0001-7816-0547"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Xin Cheng","raw_affiliation_strings":["1Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113589490","display_name":"Changli Qian","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Changli Qian","raw_affiliation_strings":["1Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5043714628","display_name":"Jean J. Zhao","orcid":"https://orcid.org/0000-0002-4561-5688","observed_orcids":["https://orcid.org/0000-0002-4561-5688"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jean Zhao","raw_affiliation_strings":["1Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210117453"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"82","issue":"12_Supplement","first_page":"LB004","last_page":"LB004"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11313","display_name":"Immune cells in cancer","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10769","display_name":"BRCA gene mutations in cancer","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1311","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/parp-inhibitor-resistance","display_name":"PARP inhibitor resistance","score":0.8899999856948853},{"id":"https://openalex.org/keywords/secondary-resistance","display_name":"secondary resistance","score":0.6620000004768372},{"id":"https://openalex.org/keywords/stat3-signaling","display_name":"STAT3 signaling","score":0.8949999809265137},{"id":"https://openalex.org/keywords/high-grade-serous-ovarian-carcinoma","display_name":"high-grade serous ovarian cancer","score":0.9739999771118164},{"id":"https://openalex.org/keywords/tumor-associated-macrophages","display_name":"tumor-associated macrophages","score":0.9539999961853027},{"id":"https://openalex.org/keywords/tumor-microenvironment","display_name":"tumor microenvironment","score":0.7829999923706055},{"id":"https://openalex.org/keywords/m2-macrophage-polarization","display_name":"M2 macrophage polarization","score":0.8690000176429749},{"id":"https://openalex.org/keywords/sting-agonist","display_name":"STING agonist","score":0.8930000066757202},{"id":"https://openalex.org/keywords/myeloid-reprogramming","display_name":"myeloid reprogramming","score":0.8259999752044678},{"id":"https://openalex.org/keywords/dendritic-cell-activation","display_name":"dendritic cell activation","score":0.847000002861023},{"id":"https://openalex.org/keywords/tumor-infiltrating-t-cells","display_name":"tumor-infiltrating T cells","score":0.8240000009536743},{"id":"https://openalex.org/keywords/immunosuppressive-tumor-microenvironment","display_name":"immunosuppressive tumor microenvironment","score":0.8859999775886536}],"concepts":[{"id":"https://openalex.org/C2776107976","wikidata":"https://www.wikidata.org/wiki/Q1786433","display_name":"Tumor microenvironment","level":3,"score":0.7593402862548828},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.7533642053604126},{"id":"https://openalex.org/C2780427987","wikidata":"https://www.wikidata.org/wiki/Q172341","display_name":"Ovarian cancer","level":3,"score":0.595116913318634},{"id":"https://openalex.org/C127561419","wikidata":"https://www.wikidata.org/wiki/Q224527","display_name":"Downregulation and upregulation","level":3,"score":0.5571755170822144},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.48780110478401184},{"id":"https://openalex.org/C2779482015","wikidata":"https://www.wikidata.org/wiki/Q17121648","display_name":"Tumor-associated macrophage","level":4,"score":0.47508350014686584},{"id":"https://openalex.org/C2778923194","wikidata":"https://www.wikidata.org/wiki/Q14912019","display_name":"STAT3","level":3,"score":0.46136561036109924},{"id":"https://openalex.org/C2780084626","wikidata":"https://www.wikidata.org/wiki/Q11793790","display_name":"Ovarian tumor","level":4,"score":0.4611506760120392},{"id":"https://openalex.org/C182979987","wikidata":"https://www.wikidata.org/wiki/Q3907241","display_name":"Poly ADP ribose polymerase","level":4,"score":0.46092933416366577},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.34894537925720215},{"id":"https://openalex.org/C62478195","wikidata":"https://www.wikidata.org/wiki/Q828130","display_name":"Signal transduction","level":2,"score":0.30197060108184814},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.27389803528785706},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.1553889811038971},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.1195513904094696},{"id":"https://openalex.org/C3020616263","wikidata":"https://www.wikidata.org/wiki/Q1216998","display_name":"Tumor cells","level":2,"score":0.0866827666759491},{"id":"https://openalex.org/C82381507","wikidata":"https://www.wikidata.org/wiki/Q416878","display_name":"Polymerase","level":3,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2022-lb004","doi":"https://doi.org/10.1158/1538-7445.am2022-lb004","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2022-lb004","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4308399413","https://openalex.org/W4313645189","https://openalex.org/W3182066591","https://openalex.org/W4200215809","https://openalex.org/W7155380170","https://openalex.org/W4281673144","https://openalex.org/W3039299171","https://openalex.org/W2903718866","https://openalex.org/W4281634224","https://openalex.org/W4233287672"],"abstract_inverted_index":{"Abstract":[0],"PARP":[1,43,64,78,126,212,249],"inhibitors":[2],"(PARPi)":[3],"have":[4],"demonstrated":[5,130],"potent":[6],"therapeutic":[7,40,209],"efficacy":[8],"in":[9,23,72,85,89,96,105,114,123,137,152,162,183,214,237],"patients":[10],"with":[11],"ovarian":[12,51,100,141,165,184,215],"cancer.":[13,101],"However,":[14],"acquired":[15],"resistance":[16,29,41,62,180,198,210,244],"to":[17,38,42,63,125,176,181,205,211,248],"PARPi":[18,182,197],"is":[19],"a":[20,56,60,153,193,201,241],"major":[21],"challenge":[22],"the":[24,28,73,81,97,115,138,178,207,255],"clinic.":[25],"Therefore,":[26],"understanding":[27],"mechanism":[30,58,195],"and":[31,117,147,199],"developing":[32],"new":[33,57,194,202],"treatment":[34,203],"approaches":[35],"are":[36],"important":[37],"overcome":[39,177,206],"inhibition.":[44,127],"By":[45],"using":[46],"our":[47],"GEM":[48],"of":[49,94,99,103,110,140,196,234,245,254],"Brca1-deficient":[50],"tumor":[52,68,74,86,106,119,142,166,238],"model,":[53],"we":[54,129,169],"uncovered":[55],"underlying":[59],"secondary":[61,179,243],"inhibition":[65,79,213,250],"mediated":[66],"by":[67,187],"associated":[69],"macrophages":[70,113,146],"(TAMs)":[71],"microenvironment":[75],"(TME).":[76],"Mechanistically,":[77],"induced":[80],"STAT3":[82,104,235],"signaling":[83,236],"pathway":[84],"cells,":[87],"which":[88],"turn":[90],"promoted":[91],"pro-tumor":[92,112],"polarization":[93,109],"TAMs":[95],"TME":[98,116,139],"Ablation":[102],"cells":[107,122,136,150,239],"mitigated":[108],"M2-like":[111],"increased":[118],"infiltration":[120],"T":[121],"response":[124],"Furthermore,":[128],"that":[131,171],"STING":[132,172],"agonists":[133],"reprogramed":[134],"myeloid":[135,154],"into":[143],"antitumor":[144],"M1-like":[145],"activated":[148],"dendritic":[149],"(DCs)":[151],"cell":[155],"STING-dependent":[156],"manner.":[157],"These":[158],"findings":[159],"were":[160],"recapitulated":[161],"patient-derived":[163],"PARPi-resistant":[164],"models.":[167],"Finally,":[168],"show":[170],"agonism":[173],"was":[174],"able":[175],"cancer":[185],"rendered":[186],"immunosuppressive":[188],"TME.":[189],"Our":[190],"study":[191],"elucidates":[192],"provides":[200],"strategy":[204],"TME-induced":[208],"cancers.":[216],"Citation":[217],"Format:":[218],"Liya":[219],"Ding,":[220],"Qiwei":[221],"Wang,":[222],"Michael":[223],"Kearns,":[224],"Tao":[225],"Jiang,":[226],"Xin":[227],"Cheng,":[228],"Changli":[229],"Qian,":[230],"Jean":[231],"Zhao.":[232],"Upregulation":[233],"fosters":[240],"TME-dependent":[242],"BRCA1-deficient":[246],"HGSOC":[247],"[abstract].":[251],"In:":[252],"Proceedings":[253],"American":[256],"Association":[257],"for":[258],"Cancer":[259,270],"Research":[260],"Annual":[261],"Meeting":[262],"2022;":[263],"2022":[264],"Apr":[265],"8-13.":[266],"Philadelphia":[267],"(PA):":[268],"AACR;":[269],"Res":[271],"2022;82(12_Suppl):Abstract":[272],"nr":[273],"LB004.":[274]},"counts_by_year":[],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2022-06-17T00:00:00"}